Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Macromol Biosci. 2020 Mar 20;20(5):e1900445. doi: 10.1002/mabi.201900445

Figure 2.

Figure 2.

Observational records for bodyweight and RA score. A. Mice bodyweight in booth of DFMT and 18B12 groups showed increase along with RA progress. B. DFMT showed significant effect in inhibiting RA progress, similar to 18B12 treatment. Stastistics: one-way ANOVA plus Tukey’s post-hoc test (P < 0.001 = ***, not significant = n.s.)